Passion – Teamwork – Expertise

 

Pulmonary diseases are on the rise, and mean a substantial burden on patients, caregivers, and society. Specific unmet needs are still present in the areas of Cystic Fibrosis, Asthma and COPD.

 

We at Nommapharma are driven by helping those patients and society by using good science that leads to good clinical development. Ultimately, it is our goal to improve people's lives with intelligent and ethical application of clinical science. Our team of experienced drug development professionals is working virtually, and brings a long history of successful drug development in the pulmonary space, along with regulatory expertise, and understanding of the business needs.

 

Nommapharma is a US based company focused on development of drugs to treat pulmonary diseases. Based on innovative technology we discover and develop drugs to change the lives of patients around the world. Founded by experienced entrepreneurs and skilled development scientists we strive to make an impact on people suffering from pulmonary disease.

 

 

 

COPD

COPD is an obstructive lung disease characterized by chronic inflammation, poor airflow, and deterioration over time. The symptoms include shortness of breath, sputum production and chronic cough. COPD is a large and growing burden to society, with increasing patient numbers in the developing world.

 

Cystic Fibrosis

Cystic fibrosis is an autosomal recessive genetic disorder that affects multiple organs, and is characterized by abnormal transport of chloride and sodium across the epithelium, leading to thick, viscous secretions. This results in frequent and chronic lung infections that requires treatment with antibiotics and other medications, both systemic and inhaled. The main burden of disease is the lung and pulmonary complications, with difficulty breathing as a hallmark of the disease.

 

Asthma

As a common chronic inflammatory disease of the airways, Asthma is characterized by reversible airflow obstruction, bronchospasm and variable symptoms. Frequent symptoms are coughing, wheezing, chest tightness and shortness of breath. Moderate and severe asthma are characterized by frequent exacerbations, reduction of Quality of Life, and frequent absence from work or school.

 

Nommapharma is in the process of developing novel approaches in the above indications, and will announce specfics of those programs shortly.